Semaglutide vs. Tirzepatide: The Basic Difference

Semaglutide and tirzepatide are active ingredients, not two names for the same medicine. Semaglutide is a glucagon-like peptide-1, or GLP-1, receptor agonist. It selectively activates the GLP-1 receptor, which is involved in appetite and calorie intake as well as glucose-dependent insulin release and glucagon regulation. Tirzepatide activates that same GLP-1 receptor and a second target, the glucose-dependent insulinotropic polypeptide, or GIP, receptor. That is why you may see tirzepatide described as a dual GIP/GLP-1 receptor agonist.

The overlap explains why the medicines can seem similar. Both can decrease calorie intake through effects on appetite, help lower blood glucose, and delay stomach emptying. Tirzepatide's added GIP activity is a real biological difference, but it does not mean you can translate the comparison into a simple formula such as “two pathways equals twice the effect.” The size of any benefit and the chance of side effects depend on the product, the population studied, the outcome measured, and the individual using it.

The clearest shorthand is: semaglutide targets GLP-1; tirzepatide targets GIP and GLP-1. They belong to an overlapping family of incretin-based medicines, but they are different molecules with different FDA labels. They should not be treated as dose-for-dose substitutes or assumed to be interchangeable.

Brand names tell you which regulated product—and which FDA-approved use—is being discussed. Wegovy and Ozempic contain semaglutide. Zepbound and Mounjaro contain tirzepatide. Sharing an active ingredient does not give two brands identical indications, formulations, strengths, or instructions.

Wegovy is approved for long-term weight reduction in certain adults with obesity or overweight and, for its injection, certain adolescents with obesity. Its current label also includes cardiovascular risk reduction for adults with established cardiovascular disease and obesity or overweight. Wegovy injection has an accelerated approval for certain adults with noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, and moderate to advanced liver fibrosis. Ozempic is a type 2 diabetes product for adults; its label also includes specific cardiovascular and kidney risk-reduction indications in defined groups of adults with type 2 diabetes.

Zepbound is approved for long-term weight reduction in certain adults with obesity or overweight. It is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is approved to improve blood sugar control in adults and children age 10 and older with type 2 diabetes.

This is why saying “I take semaglutide” or “tirzepatide is for weight loss” leaves out essential information. FDA approval attaches to a specific product, population, and purpose. Ask for the exact brand, formulation, indication, and current prescribing information before comparing two options.

There is direct comparative evidence, but it answers a narrower question than many headlines imply. In the SURMOUNT-5 trial, adults with obesity but without type 2 diabetes were randomly assigned to maximum tolerated weekly injectable tirzepatide or semaglutide for 72 weeks. Tirzepatide produced a greater average reduction in body weight and waist circumference at the study's endpoint. The trial was open-label and funded by Eli Lilly, tirzepatide's manufacturer.

That result is useful when the question resembles the study question. It does not prove that tirzepatide is “best” for every person, every condition, or every health outcome. The trial did not include people with type 2 diabetes, and its group averages cannot tell you which medicine you will tolerate, how much weight you will lose, or whether you will stay on treatment. It also does not erase product-specific evidence—for example, FDA-approved cardiovascular, kidney, liver, or sleep-apnea indications that apply only to particular brands and patient groups.

Be cautious when comparing percentages from separate trials. Different studies may enroll different people, last for different periods, use different doses or formulations, handle treatment discontinuation differently, and provide different lifestyle support. A fair comparison starts with a true head-to-head study, then checks whether its participants, products, outcomes, and follow-up match the question you are asking.

The safety profiles overlap substantially. Across the current labels, nausea, diarrhea, vomiting, constipation, and abdominal pain are among the common adverse reactions. Because both medicines affect the digestive system and delay stomach emptying, tolerability can influence whether a person can continue treatment. Raw side-effect percentages from different labels should not be compared as if they came from one identical experiment.

All four products carry a boxed warning about thyroid C-cell tumors observed in rodents. The labels say it is unknown whether semaglutide or tirzepatide causes these tumors, including medullary thyroid carcinoma, in humans. The products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. A history of a serious hypersensitivity reaction to the active ingredient or product components is also a contraindication.

Important warnings and precautions include pancreatitis, gallbladder disease, acute kidney injury related to volume depletion, severe gastrointestinal reactions, serious allergic reactions, and low blood sugar when used with insulin or certain insulin-releasing diabetes medicines. Labels also address diabetic retinopathy in relevant patients and rare reports of pulmonary aspiration during general anesthesia or deep sedation.

This is not a complete safety list. Before treatment, a licensed clinician needs your medical history, symptom history, and full medication list. During treatment, new or severe symptoms deserve prompt clinical review rather than advice from a comment thread.

The comparison changes when other medicines, pregnancy plans, procedures, and product source enter the picture. Both ingredients delay stomach emptying and can affect how some oral medicines are absorbed. When either is combined with insulin or an insulin secretagogue, the risk of low blood sugar may rise. Tirzepatide labels contain a specific warning that oral hormonal contraceptives may be less effective after treatment begins and after dose increases. Semaglutide labels account for its long washout period when discussing a planned pregnancy. Pregnancy, breastfeeding, and contraception questions need product-specific guidance from a licensed clinician.

Tell every clinician involved in your care—including the team planning anesthesia or deep sedation—that you use one of these medicines. Current labels describe rare postmarketing reports of pulmonary aspiration in this setting and say available evidence is insufficient to establish one universal risk-reduction strategy. That makes individualized procedural planning important.

Source matters too. A compounded product is not the same FDA-approved product as Wegovy, Ozempic, Zepbound, or Mounjaro. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing and has warned about dosing errors, fraudulent labels, and semaglutide salt forms that differ from the active ingredient in approved drugs. Verify the exact product, prescriber, pharmacy, and package rather than relying on an advertisement that uses only the ingredient name.

A useful comparison is less about choosing a universal winner and more about matching the right evidence to the right person. Start by writing down the exact product and active ingredient. Then confirm the FDA-approved purpose being considered: long-term weight reduction, type 2 diabetes management, cardiovascular or kidney risk reduction, obstructive sleep apnea, or another product-specific indication. The brand label—not the ingredient's online reputation—defines what has been reviewed.

Next, bring a licensed clinician your health history, current medications and supplements, prior digestive or gallbladder problems, diabetes complications, pregnancy plans, and any upcoming procedure involving anesthesia or deep sedation. Ask what benefits matter for your situation beyond the scale, what side effects require contact, and how progress, hydration, nutrition, physical activity, and preservation of muscle and function will be monitored.

Finally, check practical continuity. Confirm that the product comes from a lawful pharmacy, learn what follow-up is included, and calculate costs beyond the advertised medication price. Coverage can depend on the brand and indication, even when two brands share an ingredient. Ask what happens if side effects, supply problems, or insurance changes interrupt the plan.

If you cannot name the product, approved use, source, prescriber, and follow-up path, you do not yet have enough information for a meaningful comparison. The biological difference is the starting point; safe, useful decision-making remains product-specific and person-specific.